利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

58 条记录 (耗时 0.032 秒)

    WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS
    3.
    发明申请
    WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS 失效
    用于治疗骨质疏松症和/或骨质疏松症的水溶性UM条

    公开(公告)号：US20100048697A1

    公开(公告)日：2010-02-25

    申请号：US12535053

    申请日：2009-08-04

    申请人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    IPC分类号： A61K31/28

    CPC分类号： A61K33/24 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C59/08 ,  C07C59/19 ,  C07C59/347

    摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

    摘要翻译： 用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。 化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。 新的水溶性锶盐的实例是例如。 谷氨酸锶和α-酮戊二酸锶。 本发明还涉及一种制备谷氨酸锶盐的改进方法。

    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
    4.
    发明授权
    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
    用于治疗软骨和/或骨骼状况的水溶性锶盐

    公开(公告)号：US07595342B2

    公开(公告)日：2009-09-29

    申请号：US11269289

    申请日：2005-11-07

    申请人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    IPC分类号： A61K31/19

    CPC分类号： A61K33/24 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C59/08 ,  C07C59/19 ,  C07C59/347

    摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

    摘要翻译： 用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。 化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。 新的水溶性锶盐的实例是例如。 谷氨酸锶和α-酮戊二酸锶。 本发明还涉及一种制备谷氨酸锶盐的改进方法。

    Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
    5.
    发明授权
    Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions 失效
    用于预防或治疗坏死性骨质状况的含锶化合物

    公开(公告)号：US08609616B2

    公开(公告)日：2013-12-17

    申请号：US13182798

    申请日：2011-07-14

    申请人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Henry G Bone, III

    发明人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Henry G Bone, III

    IPC分类号： A61P19/08

    CPC分类号： A61K33/24 ,  A61K31/28 ,  A61K31/56 ,  A61K31/57 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

    摘要： A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

    摘要翻译： 用于治疗和/或预防有需要的哺乳动物中的骨坏死性骨病的方法，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死，Legg-Calve-Perthes疾病和股骨 头坏死，所述方法包括向哺乳动物施用有效剂量的含锶化合物（a）。 用于治疗和/或预防将要或被治疗的哺乳动物中的骨坏死性骨病，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死的方法 具有已知或怀疑诱导骨细胞凋亡和/或坏死的治疗剂（b），该方法包括与（b）组合施用含锶化合物（a）。

    Method of Improving Treatments in Rheumatic and Arthritic Diseases
    9.
    发明申请
    Method of Improving Treatments in Rheumatic and Arthritic Diseases 审中-公开
    改善风湿性关节炎疾病治疗方法

    公开(公告)号：US20090035315A1

    公开(公告)日：2009-02-05

    申请号：US11629613

    申请日：2005-06-17

    申请人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    发明人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    IPC分类号： A61K39/395 ,  A61K31/662 ,  A61K31/351 ,  A61K31/715 ,  A61K31/724 ,  A61K31/192 ,  A61K31/18 ,  A61K31/167 ,  A61K31/60 ,  A61K31/235 ,  A61K31/5415 ,  A61K31/56 ,  A61K38/00 ,  A61K31/415

    CPC分类号： A61K31/519 ,  A61K31/28 ,  A61K31/403 ,  A61K31/573 ,  A61K31/65 ,  A61K31/663 ,  A61K31/7008 ,  A61K31/737 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.

    摘要翻译： 改善关节疾病的治疗，例如， 骨关节炎和类风湿性关节炎以及疼痛，其中单独施用含锶化合物或与一种或多种第二治疗和/或预防活性物质组合施用，所述第二治疗和/或预防活性物质选自二膦酸盐，葡糖胺，扑灭剂，止痛剂，疾病 修饰抗风湿化合物（DMARD），选择性雌激素受体调节剂（SERM），芳香酶抑制剂，非甾体抗炎药（NSAID），COX-2抑制剂，COX-3抑制剂，阿片样物质，IL-1抑制剂/拮抗剂 ，TNF-α的抑制剂/拮抗剂，基质金属蛋白酶（MMPs）的抑制剂，组织蛋白酶K抑制剂，RANK-配体的抑制剂/拮抗剂，他汀类，糖皮质激素，硫酸软骨素，NMDA受体拮抗剂，白细胞介素-I转化酶抑制剂， 降钙素基因相关肽拮抗剂，甘氨酸拮抗剂，香草素受体拮抗剂，诱导型一氧化氮合成酶抑制剂（iNOS），N-乙酰 胆碱受体激动剂，神经激肽拮抗剂，精神抑制剂，PAR2受体拮抗剂和作用于关节组织成分的合成代谢生长因子。 包含含锶化合物和如上定义的第二治疗和/或预防活性物质的药物组合物。